See other companies on Welcome to the Jungle
Freenome
Biological analysis platform for cancer
- 201-500 employees
- Healthcare
- B2B
- Biology
- Machine Learning
- MedTech
- The East Side, South San Francisco, CA
Jump to section
Company mission
To create tools that empower everyone to prevent, detect, and treat their disease.
Our take
Freenome is a biotechnology company offering a biological analysis platform that uses molecular biology and machine learning to detect cancer with a routine blood draw. The platform trains on thousands of cancer-positive blood samples to recognise disease-associated patterns and help detect early-stage cancer, allowing clinicians to optimise treatments.
The company specialises in advanced computational biology, using machine learning to detect patterns among billions of circulating cell-free biomarkers. Freenome continues to focus on the development of its colorectal cancer test, potentially helping the 45 million people not currently up-to-date on colorectal cancer screening guidelines in the United States.
Following its 2022 funding round, the company surpassed the $1 billion funding mark. Freenome is set to accelerate the development of its platform, testing for additional cancers and furthering its blood test detection technology. It's also forming partnerships for R&D purposes, joining forces with health firms such as Geisinger to provide real-world data that could help it detect multiple cancers.
Steph
Company Specialist at Welcome to the Jungle
Company values
- Strive for Greatness: We choose to take on cancer not because it's easy, but because it's hard
- Servant Leadership: We lead by example and help others grow to their full potential
- Trust: We recognize trust is built over time and value long-term relationships, not short-term transactions
- Integrity: We courageously do what is right, and are fact-based, data-driven, and accountable for results
- Empathy: We seek to understand before being understood and build products that equitably serve diverse communities
Funding (last 2 of 7 rounds)
Feb 2024
$254m
LATE VC
Dec 2021
$300m
SERIES D
Total funding: $1.1bn
This company has top investors
Leadership
Riley Ennis
(Co-Founder & PO)Studied at Yale, Johns Hopkins and Dartmouth. Was a Thiel Fellow and co-founded Immudicon and Oncolinx.
Articles
Jobs (5)
Software Engineering
Marketing
Operations & Strategy